JPRN-UMIN000004906已完成2 期
Open trial of the interferon therapy for withdrawal of entecavir for patient with chronic hepatitis B - Open trial of the interferon therapy for withdrawal of entecavir for patient with chronic hepatitis B
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 个研究点目标入组 15 人开始时间: 2011年1月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1,allergy with entecavir, interferon or vaccination 2,interferon treatment before 6 months of the trial 3,pregnancy or lactation period 4,severe heart disease, chronic renal failure, depression, severe psychotic disease, liver cirrhosis, brain hemorrhage or infarction, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, HCV infection, autoimmune disease 5,treated with shosaiko-to
研究者
相似试验
招募中
不适用
Randomised clinical trial of interferon rebound therapy for chronic hepatitisB patientschronic hepatitis BJPRN-UMIN000009159Toranomon Hospital100
招募中
3 期
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100
进行中（未招募）
1 期
The purpose of this study is to evaluate how effective, safe and tolerable Sofosbuvir (SOF)/Velpatasvir(VEL) is when taken by people with recent hepatitis C virus (HCV) infection, in particular whether the length of treatment can be shortened. Study participants will be randomly (occur by chance) assigned into one of the two different groups. The short treatment duration group will receive SOF/VEL for 6 weeks and the standard treatment duration group will receive SOF/VEL for 12 weeks.Recent hepatitis C virus infection all genotypes.MedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004243-39-NLniversity of New South Wales Australia250
进行中（未招募）
1 期
A study to evaluate how effective, safe and tolerable Sofosbuvir/Velpatasvir is when taken by people with recent hepatitis C virus infection, in particular whether the length of treatment can be shortened.Recent hepatitis C virus infection all genotypes.MedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004243-39-GBThe University of New South Wales Australia250
进行中（未招募）
1 期
Essai pilote évaluant un traitement antirétroviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et l’etravirine (TMC125) chez les patients infectés par le VIH-1, en échec virologique et porteurs de virus multi-résistants. - TRIOEUCTR2007-000670-23-FRAgence nationale de recherches sur le sida et les hépatites virales. ANRS